Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Mingren Freda Pharmaceutical
Jinan, Shandong, Chinac-p-f.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shandong Mingren Freda Pharmaceutical is engaged mostly in generics and APIs, notably performing bioequivalence studies for drugs such as tofacitinib citrate (JAK inhibitor, generic of Pfizer’s Xeljanz). Additional published work includes early pharmacology and drug delivery research. No novel clinical efficacy data for novel therapeutics identified; the company is primarily focused on manufacturing, development, and regulatory equivalence research for established drugs.[9]
- Therapeutic areas
- OtherImmunologyRheumatology
- Modalities
- Small moleculeBiologic conjugate
- Industry
- Chemicals & Materials
Beyond the preview
Go deeper on Shandong Mingren Freda Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Mingren Freda Pharmaceutical.